Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Queen Mary University of London, Barts Cancer Institute, Dana-Farber Cancer Institute, Yale University, Smilow Cancer Hospital, University of California, San Francisco, University of Tsukuba, Azienda Ospedaliera San Camillo-Forlanini, Merck & Co., Inc., Rahway, NJ, USA (United States), Incyte (United States), University of Michigan
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890283163